May 23, 2023 – Reapplix announced its 3C Patch® Wound Management System has received an Innovative Technology contract from Vizient, Inc.
The patented 3CPatch® System is an innovative, evidence-based biological wound therapy made entirely from the patient’s own blood. It is only three-layer leukocyte fibrin-rich patch backed by extensive clinical research, including a large (n=269), randomized controlled trial published in The Lancet, 2018, showing that product significantly increases the chance of healing.
Effective April 13, 2021, Medicare published a National Coverage Determination for the 3C Patch for the treatment of chronic nonhealing diabetic wounds for 20 weeks.
The contract was awarded based on the recommendation of 3C Patch by hospital experts who serve on one of Vizient’s member-led councils, and it signifies to Vizient members unique qualities that potentially bring improvement to the healthcare industry.
Innovative Technology contracts are recommended after review and interaction with products submitted through Vizient’s Innovative Technology Program. Vizient member-led councils identify technologies that have the potential to enhance clinical care, patient safety, health care worker safety or improve business operations of health care organizations.